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The epidermal growth factor receptor and its ligands
initiate a major signaling pathway that regulates kera-
tinocyte growth in an autocrine manner. It is well
known that high doses of epidermal growth factor re-
ceptor ligands inhibit keratinocyte growth. Recently,
signal transducers and activators of transcription 1-de-
pendent p21Waf1/Cip1 induction were reported to be in-
volved in high-dose epidermal growth factor-
dependent cell growth arrest in the A431 squamous cell
carcinoma cell line; however, transfection of dominant-
negative signal transducers and activators of transcrip-
tion 1 adenovirus vector did not block epidermal
growth factor-induced growth inhibition in normal
human keratinocytes. As transforming growth factor b
is a potent inhibitor of keratinocyte proliferation, we
hypothesized that transforming growth factor b contri-
butes to epidermal growth factor-mediated keratino-
cyte growth inhibition. Epidermal growth factor
concentrations of 10 ng per ml enhanced transforming
growth factor b1 mRNA expression from 3 to 6 h post-
stimulation. Enzyme-linked immunosorbent assay ana-
lysis detected 150 pg per ml of transforming growth
factor b1 in the culture medium of keratinocytes incu-
bated with 10 and 100 ng per ml epidermal growth fac-
tor, whereas 0.1 and 1.0 ng per ml epidermal growth
factor slightly enhance transforming growth factor b1
production. Epidermal growth factor (100 ng per ml)
upregulated luciferase activity of p3TP-lux, which con-
tains three tandem transforming growth factor b-Smad
signaling responsive elements, 6-fold compared with
unstimulated cells. The epidermal growth factor-de-
pendent induction of p3TP-lux luciferase activity was
disrupted by transfection of the dominant negative
form of transforming growth factor b type I receptor
adenovirus vector (AxdnALK5), which suggests that
epidermal growth factor-induced transforming growth
factor b acts in an autocrine manner in keratinocytes.
Moreover, transfection of AxdnALK5 completely
blocked the growth inhibition induced by 100 ng per
ml of epidermal growth factor in normal keratinocytes.
These data demonstrate that an autocrine transforming
growth factor b1-ALK5 pathway is a negative feedback
mechanism for epidermal growth factor-induced nor-
mal human keratinocyte growth. Key words: keratino-
cyte/epidermal growth factor/transforming growth factor b/
activin receptor-like kinase/signal transducers/activators of
transcription. J Invest Dermatol 120:1030 ^1037, 2003
T
he binding of epidermal growth factor (EGF) family
ligands to EGF receptors (EGFR) initiates a major
signaling pathway that regulates epithelial cell
growth (Gusterson et al, 1984; Johnson et al, 1993;
Alison and Sarraf, 1994; Filipe et al, 1995; Rajagopal
et al, 1995). Some types of breast cancer cells have abundant
EGFR, and EGFR plays a crucial part in breast cancer tumor
progression (Battaglia et al, 1988; Bevilacqua et al, 1990; Toi et al,
1990). Although the A431 squamous carcinoma cell line has abun-
dant EGFR, high doses of EGF inhibit A431 cell growth (Gill
and Lazar, 1981; Barnes, 1982).
The EGF family, which includes heparin-binding epidermal
growth factor-like growth factor, transforming growth factor
(TGF)-a, and amphiregulin, is well known as an auto-
crine growth factor for normal human keratinocytes (Co¡ey
et al, 1987; Cook et al, 1991; Hashimoto et al, 1994; Shirakata
et al, 2000). Similar to A431 cells, low doses of EGF, heparin-
binding-EGF, and epiregulin stimulation promote keratinocyte
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growth, whereas high doses of 10^100 ng per ml inhibit prolif-
eration (Hashimoto et al, 1994; Chen et al, 1995; Shirakata et al,
2000).
EGFR internalization occurs after the binding of EGFR li-
gands (Gusterson et al, 1984; Lehtola et al, 1989; Bevilacqua et al,
1990). This downregulation is one of the EGFR signal regulatory
mechanisms (Masui et al, 1993; Skarpen et al, 1998); however, the
mechanism of EGF-dependent growth inhibition has yet to be
fully assessed in keratinocytes. Recently, some groups reported
that in A431 cells, the cyclin-dependent kinase (CDK) inhibitor
p21 is involved in EGF-dependent cell growth arrest (Jakus and
Yeudall, 1996; Ohtsubo et al, 1998; Skarpen et al, 1998), and that
EGF-dependent STAT (signal transducers and activators of tran-
scription) 1 activation induces p21 (Bromberg et al, 1998; Ohtsubo
et al, 2000); however, our preliminary experiment shows that
transfection of dominant-negative STAT1 adenovirus vector did
not block the growth inhibition dependent on high-dose EGF
in human primary keratinocytes. These data suggest that another
molecule is involved in EGF-induced growth inhibition in these
cells.
Interferon (IFN)-g and TGF-b are potent inhibitors of kerati-
nocyte proliferation (Nickolo¡ et al, 1984; Matsumoto et al, 1990).
In keratinocytes, IFN-g stimulation activates STAT1 and induces
transcription of the CDK inhibitor p21. TGF-b binds to TGF-b
type II receptor, which then phosphorylates the TGF-b type I re-
ceptor (activin receptor-like kinase 5; ALK5). Phosphorylated
ALK5 recruits and activates the signal transduction molecules
Smad2 and Smad3 (Attisano andWrana, 2000; Datto andWang,
2000; Massague andWotton, 2000; Miyazono, 2000). TGF-b in-
duced G0/G1 phase cell cycle arrest of various cells (Longstreet
et al, 1992; Reddy et al, 1994), and TGF-b induces the CDK inhi-
bitors p27 and p16 in keratinocytes and inhibits cell proliferation
(Hannon and Beach, 1994; Ewen, 1996). Keratinocyte IFN-g pro-
duction is species dependent; there are reports that human kerati-
nocytes produce IFN-g, whereas murine keratinocytes do not
(Howie et al, 1996; Akiba et al, 2001). On the other hand, both hu-
man and murine keratinocytes produce TGF-b1 and TGF-b2
(Bascom et al, 1989; Glick et al, 1990; Keski-Oja and Koli, 1992).
The activator protein-1 site in the TGF-b promoter region is sti-
mulated by growth factors through mitogen-activated protein ki-
nase activation (Salbert et al, 1993; Rak et al, 1995). The EGF
family phosphorylates EGFR, and EGFR activates mitogen-acti-
vated protein kinases, phosphatidylinositol 3 kinase, STAT, and G
proteins (Nakamura et al, 1996; Grandis et al, 1998; Toyoda et al,
1998; Hackel et al, 1999; Liebmann, 2001). Therefore, we hypothe-
size the involvement of TGF-b in high-dose EGF-dependent
keratinocyte growth inhibition. This study demonstrates that in-
hibiting TGF-b receptor signaling results in the suppression of
high-dose EGF-induced growth inhibition in keratinocytes.
MATERIALS AND METHODS
Cell culture Normal human skin obtained from plastic surgery was cut
into 3^5 mm strips and incubated with 250 U per ml of dispase in
Dulbecco’s modi¢ed Eagle’s medium overnight at 41C. The epidermis was
separated from the dermis by forceps, and the epidermal sheets were rinsed
with phosphate-bu¡ered saline (^), incubated in a 0.25% trypsin solution
for 10 min at 371C, and teased with forceps. Epidermal cells were rinsed,
collected by centrifugation, and resuspended in MCDB153 medium
supplemented with insulin (1 mg per ml), hydrocortisone (0.5 mg per ml),
ethanolamine (0.1 mM), phosphoethanolamine (0.1 mM), CaCl2 (0.03 mM),
and bovine hypothalamic extract (BHE) (50 mg per ml). Second or third
passage cells were used for all experiments. All procedure involving
human subjects received prior approval from the ethical committee of the
Ehime University School of Medicine, and all subjects provided written
informed consent.
Reagents Recombinant IFN-g and EGF were generous gifts from
Ohtsuka Pharmaceutical Co. Ltd (Tokyo, Japan). Recombinant TGF-b1,
anti-TGF-b1 monoclonal neutralizing antibody, and normal mouse IgG
were obtained from R&D Systems (Minneapolis, MN).
Adenovirus vector construction and infection The cosmid cassette
pAxCAw (Miyake et al, 1996), control adenovirus AxCALacZ, and the
parent virus Ad5-dLX (Miyake et al, 1996) were all kind gifts from Dr
Izumi Saito (Tokyo University, Japan). Fragments of Stat1F were
subcloned into the adenovirus cosmid cassette pAxCAw. STAT1F codes a
dominant-negative mutant, which has the tyrosine phosphorylation site
substituted with phenylalanine. Adenovirus containing the CA promoter
and STAT1F (AxSTAT1F) was generated by the COS-TPC method
(Miyake et al, 1996). The cosmid DNA was mixed with the EcoT22I-
digested DNA-terminal protein complex of Ad5-dLX, and used to
cotransfect 293 cells. Recombinant viruses were generated by homologous
recombination in 293 cells. Virus stocks were prepared by a standard
procedure (Miyake et al, 1996). Concentrated, puri¢ed virus stocks were
prepared by CsCl gradient, and the virus titer was veri¢ed using a
plaque-formation assay.
Construction of the adenovirus vector expressing dominant-negative
TGF-b type I receptor, ALK5 (AxdnALK5) has been described previously
(Fujii et al, 1999).
Normal human keratinocytes were infected with adenovirus vectors at a
multiplicity of infection (m.o.i.) of 5. AxCALacZ was transfected as a
control vector.
Cell counts and reduction rate calibration Keratinocytes were seeded
at 4.0104 cells per well in six-well collagen-coated dishes (Iwaki Glass,
Tokyo, Japan) and cultured in 3 ml of MCDB153 medium with BHE.
Twenty-four hours later, the medium was replaced with fresh MCDB153
without BHE, and adenovirus vectors (m.o.i.¼5) were added. The cells
were incubated for 24 h for infection and gene expression. Then, various
concentrations of cytokines were added and the cells were incubated for a
further 96 h. For experiments with anti-TGF-b1 monoclonal neutralizing
antibody, antibody, or normal mouse IgG (1 ng per ml) was added at the
time of EGF stimulation. Cells were trypsinized, harvested, and the total
cell number was counted using a Coultert Z1 (Coulter,Tokyo, Japan). The
proliferation rates were calibrated by comparing the total number of
stimulated and unstimulated cells. The mean and SD of relative values
obtained from three independent experiments were plotted on graphs.
3-[4,5-dimethylthiazol-2-thiazolyl]-2,5-diphenyltetrazulium bro-
mide (MTT) assay Keratinocytes were seeded at 5.0103 cells per well
in 96-well collagen-coated dishes (Iwaki Glass) and cultured in 0.1 ml of
MCDB153 medium with BHE. Adenovirus vector and cytokines were
added as described for the cell counts. Ninety-six hours after stimulation,
cell proliferation was quantitated using a MTT-based assay (CellTiter96t
Non-Radioactive Cell Proliferation Assay, Promega, Madison, WI). The
optical density at 570 nm was measured using a plate reader
(Immunomini 2100, Nalge Nunc International K.K,Tokyo, Japan) and the
value obtained was subtracted from the optical density at 630 nm. The
values indicate proliferation relative to the respective unstimulated control.
The mean and SD obtained from three independent experiments were
plotted on graphs.
Ribonuclease protection assay Total cellular RNA was isolated from
cultured human keratinocytes with Isogens (Nippon Gene, Toyama,
Japan).
Single-stranded anti-sense riboprobes were prepared by in vitro
transcription of human cDNA fragments using a RiboQuants In Vitro
Transcription kit (Pharmingen, San Diego, CA) in the presence of
[a-32P]uridine triphosphate. An hCK-3 probe set (Pharmingen) was used
as a template for in vitro transcription. Samples of total RNA (10 mg each)
were hybridized with 32P-labeled riboprobe and digested with RNase
using a RiboQuants RPA kit (Pharmingen) according to the
manufacturer’s instructions. Hybridization products were separated on a
5% polyacrylamide^8 M urea gel. The gel was absorbed on to ¢lter paper,
dried, and then exposed to Kodak Biomax MSs ¢lm (Kodak, Japan) at ^
701C. Band density was analyzed using the Diversity Databaset (PDI Inc.,
New York). The relative quantities of TGF-b1 and TGF-b2 mRNA were
estimated using GAPDH as an internal reference, and normalized against
the respective relative values at 0 h post-TGF-b2 stimulation. The relative
values of TGF-b1 and TGF-b2 mRNAwere plotted on graphs.
Enzyme-linked immunosorbent assay Keratinocytes were seeded at
5.0105 cells per dish in 10 cm diameter collagen-coated dishes (Iwaki
Glass), and cultured in 10 ml of MCDB153 medium with BHE. The
medium was replaced after 48 h with fresh MCDB153 without BHE
(10 ml). Various concentrations of EGF were added and the cells were
cultured for a further 3 d. Culture media were collected and stored at ^
201C for analysis.
TGF-b1 and TGF-b2 were measured in the culture media using
QuantikineTM (R&D Systems) according to the manufacturer’s
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instructions. The optical density at 450 nm was determined using a plate
reader (Immunomini 2100, Nalge Nunc International K.K) and subtracted
from the optical density at 540 nm.The mean and SD obtained from three
independent experiments were plotted on graphs.
Luciferase assay Keratinocytes were seeded at 4.0104 cells per well in
12-well collagen-coated dishes (Iwaki Glass) and cultured in 1 ml of
MCDB153 medium with BHE. The medium was replaced 48 h later with
1 ml fresh MCDB153 without BHE, and AxdnALK5 or AxCALacZ were
transfected (m.o.i.¼5). Twenty-four hours after adenovirus transfection, 0.5
mg of p3TP-Lux (provided by J.L. Wrana), and 10 ng of pRL-CMV
(Promega) were transfected using DOTAPt (Roche Diagnostic, Tokyo,
Japan) according to the manufacturer’s instructions. p3TP-Lux contains
three tandem repeats of a TGF-b-signal responsive element, which is
activated by TGF-b stimulation (Hayashi et al, 1997). After a 10 h
transfection of the reporter gene, the medium was replaced with 1 ml fresh
MCDB153 without BHE, various concentrations of EGF, or 0.1 ng per ml
of TGF-b1, was added. The cells were harvested 72 h later, and luciferase
activity was measured using a Dual-Luciferaset Reporter Assay System
(Promega) according to the manufacturer’s instructions. Relative values
of p3TP-Lux luciferase activity were estimated using pRL-CMV
luciferase activity as an internal reference, and normalized against the
respective relative values at nonstimulation. The mean and SD of relative
values obtained from three independent experiments were plotted on
graphs.
RESULTS
STAT1 is involved in IFN-c signaling, but not in EGF-
dependent growth inhibition in keratinocytes STAT1 is
involved in EGF-dependent growth inhibition in A431
squamous carcinoma cells (Bromberg et al, 1998; Ohtsubo et al,
2000). We generated adenovirus vector expressing dominant-
negative STAT1 (AxSTAT1F), and examined the involvement of
STAT1 in primary keratinocyte proliferation. IFN-g is well
known as a potent inhibitor of primary keratinocyte growth
(Nickolo¡ et al, 1984), and it phosphorylates and activates STAT1
in keratinocytes (Jiang et al, 1994; Aragane et al, 1997; Naik et al,
1997). AxSTAT1F transfection suppressed IFN-g-dependent
keratinocyte growth inhibition, as con¢rmed by cell counts
(Fig 1b) and MTT assay (Fig 1d). Because the cell count results
represent the increase in cell number and the MTT assay results
represent total cell number, the values from these methods are
slightly di¡erent. Nevertheless, the results from both methods
show a similar pattern, suggesting that STAT1 is involved in
IFN-g-dependent keratinocyte growth inhibition, and that
AxSTAT1F works well as a dominant negative form of STAT1;
however, AxSTAT1F transfection did not a¡ect high-dose EGF-
dependent keratinocyte growth inhibition (Fig 1a,c), suggesting
the involvement of another mechanism or molecule.
Figure1. STAT1 is involved in IFN-c-dependent, but not in high doses of EGF-dependent, growth inhibition of human keratinocytes. Pri-
mary keratinocytes were seeded at 4.0104 cells per well in six-well plates and cultured in MCDB153 medium with BHE. Twenty-four hours later, the
medium was replaced with fresh MCDB153 without BHE. Adenovirus vectors (AxSTAT1F and AxCALacZ, m.o.i.¼5) were added and the cells were
incubated for 24 h. Then, the indicated concentrations of EGF (a) and IFN-g (b) were added to the keratinocyte culture medium and the cells were incu-
bated for 96 h. Cells were trypsinized, harvested, and counted, and the proliferation rates were calibrated by comparing the total numbers of stimulated and
unstimulated cells. For the MTT assay, primary keratinocytes were seeded at 5.0103 cells per well in 96-well plates. After transfection with adenovirus
vectors, the indicated concentrations of EGF (c) and IFN-g (d) were added. Ninety-six hours after stimulation, proliferation was determined by MTTassay.
The values indicate proliferation relative to the respective unstimulated control. The bars and error bars represent mean and SD of three independent
experiments. npo0.05, nnpo0.01, nnnpo0.001.
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EGFR stimulation induced TGF-b1 in keratinocytes Like
IFN-g, TGF-b suppresses keratinocyte proliferation, and TGF-b
is produced by keratinocytes (Cook et al, 1990; Matsumoto
et al, 1990). We hypothesized that TGF-b is involved in EGF-
dependent keratinocyte growth inhibition. We examined the
induction of TGF-b mRNA by EGF stimulation (Fig 2). Under
our culture conditions, TGF-b1 was dominantly expressed
without stimulation. Following 3^6 h of stimulation, 10 ng EGF
per ml enhanced TGF-b1 mRNA expression approximately 2-
fold over baseline (0 h). TGF-b2 mRNAwas also detected after
36^48 h, but TGF-b3 mRNA was not detectable. Cultured
keratinocytes typically secrete some TGF-b1, but not TGF-b2, in
culture medium without EGF stimulation (Fig 3). Although low
doses of EGF (0.1 and 1 ng per ml) slightly increased TGF-b1
secretion, higher doses of 10 and 100 ng per ml signi¢cantly
increased TGF-b1 secretion to approximately 150 pg per ml.
Enzyme-linked immunosorbent assay analysis detected no TGF-
b2 secretion in the culture medium of primary keratinocytes.
These results suggest that TGF-b1, not TGF-b2, may regulate
keratinocyte growth.
ALK5 is involved in EGF-dependent keratinocyte growth
inhibition Next we examined whether TGF-b1 induction by
EGF a¡ects keratinocyte growth by negative feedback. We
examined EGF-dependent TGF-b signal activation using the
p3TP-Lux plasmid, which contains three tandem repeats of the
TGF-b-Smad responsive element linked to the luciferase gene
(Wrana et al, 1992). After p3TP-Lux transduction various
concentrations of EGF were added. The cells were cultured for
48 h and luciferase activity was measured. Low doses of EGF
(0.1 and 1 ng per ml) did not enhance luciferase activity (Fig 4);
however, 10 and 100 ng per ml of EGF signi¢cantly enhanced the
transcription of p3TP-Lux in the same manner as TGF-b1. This
suggests that EGF induces the TGF-b-Smad signal in
keratinocytes. Furthermore, this EGF-induced luciferase activity
was suppressed by the transfection of adenovirus vector
expressing the dominant negative form of TGF-b type I
receptor, ALK5 (AxdnALK5). These data suggest that EGF
stimulation induced TGF-b signaling through TGF-b type I
receptors, and that TGF-b1 autoinduction is involved in EGF-
Figure 2. EGF upregulates TGF-b mRNA. (a) EGF (10 ng per ml) was
added to keratinocyte culture medium, and total RNAwas extracted at 0,
1, 3, 6, 12, 24, 36, and 48 h after stimulation. Total RNA was hybridized
with RNA probes, and separated on a polyacrylamide gel. Arrows on the
left side of the panel indicate predicted TGF-b1, TGF-b2, and TGF-b3
mRNA bands. L32 and GAPDH are indicated as control mRNA. (b) Re-
lative values of TGF-b1 and TGF-b2 mRNA were estimated using
GAPDH as an internal reference, and normalized against the respective re-
lative value at 0 h post-TGF-b2 stimulation.
Figure 3. EGF enhances the production of TGF-b. Keratinocytes were
seeded at 5.0105 per dish in 10 cm diameter collagen-coated dishes and
cultured in 10 ml of MCDB153 medium with BHE. Forty-eight hours la-
ter, the medium was replaced with 10 ml fresh MCDB153 without BHE.
Various concentrations of EGF (n¼ 3) were added, and the cells were cul-
tured for more than 3 d. Culture media were collected and theTGF-b1 and
TGF-b2 concentration were measured by enzyme-linked immunosorbent
assay. Error bars indicate7SD. npo0.05, nnpo0.01.
Figure 4. EGF-dependent TGF-b signal activation. Keratinocytes
were seeded at 4.0104 per well in 12-well collagen-coated dishes and cul-
tured in 1 ml of MCDB153 medium with BHE. Forty-eight hours later,
the medium was replaced with 1 ml fresh MCDB153 without BHE, and
AxdnALK5 or AxCALacZ were transfected (m.o.i.¼5). Twenty-four
hours after adenovirus transfection, 0.5 mg of p3TP-Lux (Wrana et al,
1992) and 10 ng of pRL-CMV were transfected. After a 10 h transfection
of the reporter gene, media were replaced with 1ml fresh MCDB153 with-
out BHE.Various concentrations of EGF or 0.1 ng per ml of TGF-b1were
added to the medium and the cells were incubated for 72 h. Cells were
harvested and luciferase activity was measured. Error bars indicate7SD.
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dependent p3TP-Lux transcription. Speci¢cally, EGF-induced
TGF-b1 worked in an autocrine fashion. Finally, we examined
the e¡ect of AxdnALK5 on EGF-dependent keratinocyte
growth inhibition. After AxdnALK5 transfection, EGF was
added to the cells and the increase in cell number was
determined. AxdnALK5 transfection signi¢cantly restored the 10
and 100 ng per ml EGF-dependent keratinocyte growth
inhibition to normal levels (Fig 5a,c). TGF-b1 neutralizing
antibody produced the same e¡ect as AxdnALK5 (Fig 5b,d).
These data show that autoinduction of the TGF-b1 and ALK5
signal is essential for high-dose EGF-dependent keratinocyte
growth inhibition.
DISCUSSION
The regulation of keratinocyte proliferation is self-limiting. At a
wound site, the defective epidermal lesion is re-epithelialized by
the proliferation and migration of keratinocytes. Owing to
contact inhibition, keratinocyte growth and migration stops
following re-epithelialization (Adams and Watt, 1988; Pittelkow
et al, 1993). At the wound edge, EGFR ligands are induced and
contribute to keratinocyte growth as autocrine growth factors.
The function and regulation of the EGFR signal have been dis-
cussed in wound healing and keratinocyte growth in vitro (Co¡ey
et al, 1987; Cook et al, 1991; Hashimoto et al, 1994; Shirakata et al,
2000).
The EGFR signal has biphasic e¡ects on epidermal cell
growth: low doses of EGF stimulate keratinocyte growth,
whereas high doses of EGF suppress keratinocyte proliferation.
Several reports have focused on this biphasic e¡ect. It is well
known that EGFR is internalized after ligand binding, and this
may contribute to the suppression of a continuous EGFR signal
(Gusterson et al, 1984; Lehtola et al, 1989; Bevilacqua et al, 1990;
Skarpen et al, 1998). Recent reports, however, show that EGFR
internalization modulates signal transduction in cells, and that
some signals are enhanced by EGFR internalization (Burke et al,
2001; Sorkin, 2001). Consequently, the contribution of receptor
internalization to the biphasic e¡ect of the EGF^EGFR signal re-
mains controversial.
Figure 5. TGF-b and ALK5 are involved in EGF-dependent growth inhibition of keratinocytes. Keratinocytes were seeded at 4.0104 cells per
well in six-well collagen-coated dishes and cultured in 3 ml of MCDB153 medium with BHE. Twenty-four hours later, the medium was replaced with
fresh MCDB153 without BHE. Adenovirus vectors (a) or anti-TGF-b1 monoclonal neutralizing antibody (1 ng per ml) (b) were added and the cells were
incubated for 24 h for infection and gene expression. The indicated concentrations of EGF were added and the cells were incubated for 96 h. Cells were
trypsinized, harvested, and counted, and the proliferation rates were calibrated by comparing the total numbers of stimulated and unstimulated cells. For
the MTTassay, primary keratinocytes were seeded at 5.0103 cells per well in 96-well plates. After transfection with adenovirus vectors (c), or addition of
anti-TGF-b1monoclonal neutralizing antibody (d), the indicated concentrations of EGF were added and the cells were cultured for 96 h. Proliferation was
determined by MTT assay, and the values indicate proliferation relative to the respective unstimulated control. The bars and error bars represent the mean
and SD of three independent experiments. npo0.05, nnpo0.01, nnnpo0.001.
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Some reports suggest that the EGFR signal induces the CDK
inhibitor p21 in A431 cells, and that p21 induction is an e¡ector of
EGF-dependent growth arrest in A431 cells (Jakus and Yeudall,
1996; Ohtsubo et al, 1998; Skarpen et al, 1998). Furthermore, p21
induction by the EGFR signal depends on STAT1 activation
(Bromberg et al, 1998; Ohtsubo et al, 2000). In this study, domi-
nant-negative STAT1 had no e¡ect on EGF-induced growth inhi-
bition in primary keratinocytes, although it suppressed IFN-g-
dependent keratinocyte growth inhibition (Fig 1). This indi-
cates that STAT1 is not essential for EGF-dependent growth
inhibition, but is essential for the IFN-g signal in primary
keratinocytes.
In this study, the TGF-b1 signal contributed to the regulation
of EGF-dependent primary keratinocyte proliferation. Although
primary keratinocytes produced both TGF-b1 and TGF-b2
mRNA (Fig 2),TGF-b1was dominantly secreted in the medium
under our culture conditions (Fig 3). TGF-b1 suppresses primary
keratinocyte growth (Hannon and Beach, 1994; Ewen, 1996), and
EGF enhanced the expression of TGF-b1 and TGF-b2 mRNA
and the secretion of TGF-b1. Interestingly, low doses of EGF
(0.1 ng per ml), which stimulated keratinocyte growth, did not
increase TGF-b1 secretion; however, 10 and 100 ng per ml of
EGF, which suppressed keratinocyte proliferation, signi¢cantly
increased TGF-b1 production in culture medium (Fig 3). This in-
crease inTGF-b1 secretion from about 50 pg per ml to 150 pg per
ml might be enough to suppress primary keratinocyte prolifera-
tion to some degree. Under our culture conditions, 50 pg per ml
of exogenous TGF-b1 produced only faint growth inhibition,
whereas 300 pg per ml of TGF-b1 completely suppressed kerati-
nocyte proliferation (data not shown). Over 100 pg TGF-b1 per
ml reduced keratinocyte growth by half. At 50 pg per ml,TGF-
b1 reduced keratinocyte growth by about 10%. Therefore, 10 and
100 ng per ml of EGF stimulate the production of enough TGF-
b1 to suppress keratinocyte growth. Moreover, the expression of
the dominant negative form of TGF-b type I receptor, ALK5
(AxdnALK5), recovered the growth inhibition using high-dose
EGF (Fig 5). This suggests the autocrine-induced TGF-b is a ma-
jor cause of the self-limitation of keratinocyte growth. Axd-
nALK5, however, did not enhance the keratinocyte proliferation.
Some other molecules and mechanisms might be involved in the
complicated self-limitation of keratinocytes.
TGF-b is translated as a latent form precursor and secreted in
latent form (Gleizes et al, 1997; Koli et al, 2001). Secreted latent
TGF-b is activated extracellularly by proteolytic cleavage. A po-
tential mechanism of TGF-b activation includes plasmin (Lyons
et al, 1988, 1990), thrombospondin-1 (Crawford et al, 1998; Ribeiro
et al, 1999), integrin avb1 and avb6 (Munger et al, 1998, 1999), and
matrix metalloproteinase-9 (Yu and Stamenkovic, 2000). EGF
and EGFR signaling enhance the transcription of plasminogen
activator (Jensen and Rodeck, 1993), thrombospondin (Nickolo¡
et al, 1988), and matrix metalloproteinase-9 (Zeigler et al, 1999; O-
charoenrat et al, 2000) in keratinocytes. These molecules may ac-
tivate latent TGF-b1 secreted from keratinocytes, and activated
TGF-b1 act in an autocrine manner.
Constant production of low doses of TGF-b1, which is se-
creted by keratinocytes without stimulation, may contribute to
the regulation of keratinocyte autocrine growth. TGF-b family
signals are transduced by Smad (Attisano and Wrana, 2000;
Miyazono, 2000), and TGF-b and activin phosphorylate Smad2
and Smad3. These Smad activations are regulated by several me-
chanisms. The TGF-b family signal induces transcription of
Smad6 and Smad7, which then suppress Smad signal activation
as antagonistic regulators. EGF upregulates Smad6 and Smad7
in a lung cancer cell line (Afrakhte et al, 1998), and IFN-g activates
STAT1 and upregulates Smad7 (Ulloa et al, 1999). EGF and ¢bro-
blast growth factor phosphorylate mitogen-activated protein ki-
nase, and mitogen-activated protein kinase phosphorylates the
linker domain of Smad, which suppresses Smad activity
(Kretzschmar et al, 1997). These reports suggest that basal activa-
tion of the TGF-b signal may be suppressed by a growth factor
signal. Our data indicate that high doses of EGF induced TGF-
b1 and suppressed keratinocyte growth. During the keratinocyte
growing phase, inhibitory signals from the TGF-b family might
be suppressed in normal cells; however, excessive EGFR stimula-
tion induces suppressive molecules and/or transduces suppressive
signals for keratinocyte proliferation. Consequently, the TGF-b
signal might have a pivotal role in cell growth regulation. TGF-
b1 induced by high doses of EGF suppressed unregulated kerati-
nocyte growth. Disruption and deregulation of the TGF-b signal
results in oncogenesis (Hartsough and Mulder, 1997; Klee¡ et al,
1999; Wake¢eld and Roberts, 2002); mutations in the TGF-b re-
ceptor gene are found in colon cancer, and mutations in the
Smad4 gene, a component of the TGF-b signaling molecule,
cause colon cancer (Brattain et al, 1996; Oft et al, 1998; Orimo
et al, 1998; Grady et al, 1999; Markowitz, 2000;Taketo andTakaku,
2000; Imai et al, 2001; Saha et al, 2001; Woodford-Richens et al,
2001). TGF-b induces the CDK inhibitors p16 and p27, and p16
inhibits CDK4 function. Mutations in the p16 and CDK4 genes
are found in squamous cell carcinoma, and constitutive activation
of CDK4 induces carcinoma in the epidermis (Matsumoto et al,
1999; Sou¢r et al, 1999). In addition, overexpression of EGFR in-
duces tumor formation in the epidermis (Xian et al, 1997; Xie
et al, 1999; Kiguchi et al, 2000).Therefore, EGFR signal regulation
by negative feedback fromTGF-b may be important for prevent-
ing epidermal carcinogenesis.
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